Biochemical Genetics Laboratory, Department of Biochemistry, St. James's Hospital, Dublin, Ireland; Clinical Biochemistry Unit, School of Medicine, Trinity College Dublin, Ireland.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.
Clin Chest Med. 2022 Mar;43(1):23-34. doi: 10.1016/j.ccm.2021.11.002.
The microbiology in bronchiectasis has been historically defined by culture-based analysis of the airway microbiome and to date has largely focused on the detection and eradication of specific bacterial pathogens. Although central to our current understanding of disease, microbial culture alone masks the holistic complexity of the microbiome and does not account for potential microbial interactions that define specific clinical phenotypes such as frequent exacerbators. Advances in next-generation sequencing including their analytical technologies can further complement and build upon our current understanding of the microbiology and microbiome in bronchiectasis providing improved patient stratification with prognostic significance.
支气管扩张症的微生物学在历史上是通过对气道微生物组进行基于培养的分析来定义的,迄今为止,主要集中在检测和消除特定的细菌病原体上。尽管微生物培养是我们目前对疾病理解的核心,但它掩盖了微生物组的整体复杂性,并且不能说明定义特定临床表型(如频繁加重者)的潜在微生物相互作用。包括其分析技术在内的下一代测序技术的进步可以进一步补充和扩展我们目前对支气管扩张症微生物学和微生物组的理解,为具有预后意义的患者分层提供更好的方法。